Previous Article | Next Article 
Journal of Clinical Microbiology, May 1999, p. 1398-1403, Vol. 37, No. 5
0095-1137/99/$04.00+0
Postsurgical Candida albicans Infections
Associated with an Extrinsically Contaminated Intravenous
Anesthetic Agent
Michael M.
McNeil,1,*
Brent A.
Lasker,1
Timothy J.
Lott,1 and
William R.
Jarvis2
Mycotic Diseases Branch, Division of
Bacterial and Mycotic Diseases,1 and
Investigation and Prevention Branch, Hospital Infections
Program,2 National Center for Infectious
Diseases, Centers for Disease Control and Prevention, Atlanta,
Georgia 30333
Received 2 October 1998/Returned for modification 7 January
1999/Accepted 6 February 1999
 |
ABSTRACT |
From 16 to 30 April 1990, four of 364 (1%) postsurgical patients
at one hospital developed Candida albicans fungemia or
endophthalmitis. The case patients' surgeries were clustered on two
days. To identify risk factors for C. albicans infections,
we conducted a cohort study comparing these 4 patients with 67 control
patients who had surgeries on the same days but did not acquire
C. albicans infections. The participation of
anesthesiologist 9 (relative risk [RR], undefined; P < 0.001) and receipt of intravenous propofol, an anesthetic agent
without preservative, which was administered by an infusion pump (RR,
8.8; P = 0.048) were identified as risk factors for
C. albicans infections. The anesthetic had been recently introduced in the hospital. Hand cultures of 8 of 14 (57%)
anesthesiologists were positive for Candida species; one
yielded C. albicans. Anesthesiologist 9 was the only one to
use stored syringes of propofol in the infusion pump and to reuse
propofol syringes. DNA fingerprinting with a digoxigenin-labeled
C. albicans repetitive element 2 probe and electrophoretic
karyotyping showed two distinct banding patterns among patient
isolates. We hypothesize that extrinsic contamination of propofol by
anesthesiologist 9 likely resulted in C. albicans infections. These data suggest that strict aseptic techniques must be
used when preparing and administering propofol.
 |
INTRODUCTION |
During the period June 1990 through
February 1993, personnel from the Centers for Disease Control and
Prevention (CDC) investigated seven unusual outbreaks of postoperative
infections of the bloodstream and surgical sites and acute febrile
episodes involving a variety of microorganisms after surgical
procedures in hospitals in multiple states (2). In these
outbreaks, the cause of infection was extrinsic contamination of a
lipid-based anesthetic medication, propofol. We report the findings of
an investigation of an outbreak of Candida albicans
infections in one hospital.
Hospital A is a 444-bed tertiary care center with an active surgical
program. Approximately 793 surgical procedures are performed there each
month; of these, 56% are performed on an outpatient basis and 44% are
performed on inpatients. Hospital A has 10 operating rooms (ORs) where
all surgeries are performed. In June 1990, the infection control nurse
from this hospital reported to the Hospital Infections Program,
National Center for Infectious Diseases, CDC, that three patients had
developed C. albicans wound infection with fungemia or
endophthalmitis following surgeries performed during April 1990. The
state Department of Public Health was notified, and CDC was invited to
assist in a further assessment of this apparent outbreak.
(Presented in part at the 91st Annual General Meeting of the American
Society for Microbiology, Dallas, Tex., 5 to 9 May 1991 [8a].)
 |
MATERIALS AND METHODS |
Epidemiological methods. (i) Case definition.
A case patient
was defined as any hospital A patient with a positive culture for
C. albicans from a wound and a positive blood or intraocular
culture following a surgical procedure performed between 16 and 30 April 1990. This epidemic period was chosen to include all patients who
had surgical procedures performed 1 week before the date of surgery of
the first case patients through the end of April 1990.
(ii) Case ascertainment.
To identify case patients, we
reviewed reports from infection control practitioners at other
hospitals that had admitted patients with serious postoperative
infections following surgery in hospital A. In addition, we reviewed
hospital A's microbiology records from 1 January to 8 June 1990 for
C. albicans-positive cultures, and infection control
personnel at hospital A notified surgeons so that other potentially
infected patients could be identified. We reviewed the medical charts
of all case patients identified.
(iii) Review of case patients.
We reviewed the medical
records of all case patients and abstracted information on age, sex,
race, duration of hospitalization, underlying disease, nature and date
of surgical procedures, duration of fever, receipt of therapeutic
and/or prophylactic antimicrobial agents or steroids, room assignment,
other procedures, infections, and outcome.
(iv) Cohort study.
To determine whether this cluster of case
patients represented an outbreak, we compared the rate of C. albicans wound and blood or eye infections in the epidemic and
preepidemic (1 January to 15 April 1990) periods. To assess potential
risk factors for C. albicans postsurgical infections, a
cohort study was performed. Since patients who had surgery on one of
two particular days appeared to be at greater risk of becoming
infected, we limited the cohort study to patients who had surgery on
those days, i.e., 23 April and 27 April 1990. The risk factors analyzed
included the patient's demographic and underlying health status
characteristics, exposure to intraoperative intravenous anesthesia
medications and solutions, exposure to different preoperative skin
preparations (povidone-iodine scrub or paint and shaving), exposure to
surgical drains, receipt of surgical prophylactic antimicrobial
therapy, and exposure to surgeons and anesthesia and OR nursing
personnel. During the epidemic period, 86 surgeons, 16 anesthesiologists (14 on the hospital staff), and 68 ancillary OR
nursing personnel (surgical assistants and scrub and circulating
nurses) participated in surgical procedures at hospital A.
(v) Statistical methods.
All data were collected on
standardized forms and entered into a microcomputer for analysis.
Student's t test or Fisher's exact test were used to test
for the significance of associations. When the rate ratio for a
presumed risk factor was undefined, the algorithm procedure of Thomas
and Gart was used to obtain confidence limits and a P value
(15).
Molecular subtyping methods. (i) Purification of genomic
DNA.
All isolates of C. albicans were grown for 20 h at 30°C on a rotatory shaker at 150 rpm in 10 ml of YPD broth (1%
[wt/vol] glucose, 1% [wt/vol] yeast extract [Difco Laboratories,
Detroit, Mich.], and 2% [wt/vol] Bacto Peptone [Difco]) in 50-ml
flasks. The cells were harvested by centrifugation, and then
spheroplasts were produced by the method of Scherer and Stevens
(12), using Zymolyase-20T (ICN ImmunoBiologicals, Costa
Mesa, Calif.). Genomic DNA was purified by repeated phenol-chloroform
extractions of cleared lysates as described by Mason et al.
(8).
(ii) CARE-2 Southern blot analysis.
One microgram of genomic
DNA was digested with 10 U of EcoRI (New England Biolabs,
Beverly, Mass.) or HincII at 37°C in the buffered
solutions recommended by the manufacturer. DNA fragments were separated
on a 0.7% (wt/vol) agarose gel (International Biotechnologies Inc.,
New Haven, Conn.) in Tris-borate buffer (7), stained with
ethidium bromide, and transferred to nitrocellulose filters (type BA85;
Scheicher and Schuel, Keene, N.H.) by standard protocols (7). Methods for labeling C. albicans repetitive
element 2 (CARE-2) DNA nonisotopically with digoxigenin-11-dUTP by
random priming, hybridization and washing conditions, and color
development with the Genius kit (Boehringer Mannheim, Indianapolis,
Ind.) were described previously by Lasker et al. (3).
Filters were photographed wet with Polaroid type 55 film.
(iii) Electrophoretic karyotype.
Yeast DNA plugs were
prepared as previously described (6). Transverse-alternating
field electrophoresis (TAFE) was preformed as previously described
(5), using a Geneline 1 (Beckman Instruments, Fullerton,
Calif.) chamber. Briefly, the conditions were as follows: a run time of
72 h; a 5-min pulse time; 100 V; 1× TAFE buffer (10 mM Tris base,
0.5 mM EDTA, 0.025% acetic acid), 1% agarose; 14°C. Following
electrophoresis, the gels were stained with ethidium bromide and photographed.
Procedure and personnel investigation.
To evaluate the
potential role of procedural factors, we conducted a review of the
anesthesia care of the patients by interviewing several of the
anesthesiologists and observing two surgical procedures with general
anesthesia administered by two different anesthesiologists. Hand
cultures were obtained from all 14 hospital staff anesthesiologists. All individuals wiped their hands with individually wrapped sterile handiwipes presoaked in 10 ml of 0.02% Tween 80 in water, which were
then placed into separate sterile jars containing 250 ml of Tween 80 solution in water. These specimens were then transported to CDC. After
being shaken, separate aliquots (100, 10, 1, and 0.1 ml) of each hand
culture solution were filtered through a 0.45-µm-pore-size filter.
The filters were then placed on Trypticase soy agar plates and
incubated at 30°C for 24 to 48 h, and total viable counts were determined.
Environmental investigation.
Before our on-site
investigation, hospital infection control personnel had made cultures
of swabs from equipment and solutions from the anesthetic cart of one
anesthesiologist, anesthesiologist 9. These included anesthetic agents
(two different lots of unopened ampules of propofol [Diprivan; Zeneca
Pharmaceuticals, Wilmington, Del.], vecuronium, gallamine, and
epinephrine); anesthetic equipment (forceps, medicine holder, pressure
gauge towel, paper label, plastic tubing, rubber glove, tourniquet,
lubricant, and inhalant mask); intravenous electrolyte solutions
(saline, dextrose, and Ringer's solution); remaining propofol and
saline solutions from patient intravenous administration sets; and
nonsterile water. At the time of our investigation, we repeated
environmental cultures of anesthetic equipment and medications from
anesthesiologist 9's cart, including propofol drawn up in a mock-up
intravenous pump administration set by anesthesiologist 9.
 |
RESULTS |
Case patient characteristics.
From 1 January through 8 June
1990, specimens from 62 surgical patients from hospital A were culture
positive for C. albicans: sputum (38 patients), urine (13 patients), sputum and urine (5 patients), wound (3 patients), and other
(3 patients). No eye isolates yielded C. albicans. Review of
the microbiology laboratory records identified only patient 1 (with
blood and wound cultures positive for C. albicans). The
three other case patients were identified only after they were
readmitted to other hospitals for management of C. albicans
endophthalmitis. Case ascertainment, therefore, may have been incomplete.
Of 364 patients undergoing surgical procedures during the epidemic
period, 4 (1%) developed C. albicans postsurgical
infections of the eye. There was a significant increase in the rate of
C. albicans postsurgical infections at hospital A from the
preepidemic to the epidemic period (0 of 2,555 versus 4 of 364;
P = 0.0002; Fisher's exact test), which confirmed the
presence of an outbreak of postsurgical C. albicans
infections. Case patients' surgeries were clustered, two on Monday 23 April and two on Friday 27 April 1990.
Description of case patients.
The case patients ranged in age
from 28 to 72 years; three (75%) were female (Table
1). One case patient was an inpatient at
hospital A at the time of surgery, and three underwent outpatient surgical procedures. All case patients underwent clean or
clean-contaminated surgical procedures, and all had 24-h maximum
postoperative axillary temperatures of
101°F (range, 101 to
103°F). The mean interval between the surgical procedure and the
first C. albicans-positive culture was 18 days (range, 1 to
45 days).
Cohort study.
When we compared case patients with non-case
patients, exposure to surgical drains (3 of 4 versus 14 of 67; relative
risk (RR), 9.5; P = 0.04), receipt of propofol by
infusion pump (3 of 4 versus 15 of 67; RR, 8.8; P = 0.048), and higher mean 24-h maximum postoperative temperature
(102 ± 1 versus 98.7 ± 1°F; P < 0.001)
were identified as risk factors (Table
2). When we compared the exposures of
case patients and non-case patients to the surgical, anesthesia, and OR
nursing personnel, anesthesiologist 9 and OR nurses 6 and 10 were
significantly more often associated with case patients than non-case
patients (Table 3). The independent effects of these two OR nurses could not be estimated, since their exposures were all to case patients who also received propofol by
infusion pump administered by anesthesiologist 9. However, the
magnitude of the lower bound of the confidence interval and the
calculated P value indicate that the strength of association for exposure to these two OR nurses was less than that for
anesthesiologist 9.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Potential risk factors for postoperative C. albicans infections among case patients and non-case patients,
hospital A, 23 and 27 April 1990
|
|
Results of procedural and laboratory investigations.
The
anesthesiologists had separate anesthetic carts, which when not in use
were kept in the corridor outside the anesthetic office-supply room in
the OR suite. Anesthetic medications for intravenous administration
were routinely prepared in this corridor before surgical procedures.
Propofol in 20-ml ampules was administered for induction (bolus
injection) and/or maintenance (continuous infusion by a syringe pump)
anesthesia. Anesthesiologists routinely opened medication ampules with
ungloved hands and used either a 30-ml syringe for bolus
administration of propofol or a 60-ml syringe fitted with extension
tubing for continuous propofol infusion.
Interviews with anesthesiologists revealed that the practices of
anesthesiologist 9 for the administration of propofol differed from
those of other anesthesiologists. In particular, anesthesiologist 9 prepared five syringes of propofol (two 30- and three 60-ml syringes)
before his first procedure and stored them in a drawer in his cart to
protect them from light exposure, as recommended by the manufacturer.
Propofol as a bolus for induction was administered via a 30-ml syringe,
which was then discarded after a single use. However, propofol for
maintenance or infusion anesthesia was administered via a 60-ml syringe
fitted with a three-way connector and extension tubing and placed in a
mechanical infusion pump. The pump syringe was reused for the duration
of the procedure because of concerns about medication leakage. A second
60-ml propofol syringe was used, often repeatedly, to refill the first
pump syringe via the three-way connector throughout the surgical
procedure. Unused prepared propofol syringes were routinely discarded
after periods of up to 24 h.
All environmental cultures were negative for fungi, including all of
those obtained before our on-site investigation by hospital infection
control personnel and processed by the hospital microbiology laboratory
(which included cultures of two different lots of propofol in use in
the hospital). All environmental cultures obtained and sent to CDC were
negative for fungi. Cultures of unopened ampules of intravenous
anesthetic medications, including propofol, in use at the time of the
investigation were negative for all microorganisms.
Although the hand cultures from anesthesiologists were obtained almost
2 months after the four case patients' surgical procedures, Candida species were identified on the hands of 8 (57%) of
14 anesthesiologists (Table 4). C. albicans was isolated together with other microorganisms on the
hands of one anesthesiologist, anesthesiologist 1.
Molecular subtype analysis.
To determine if case patient
isolates were genetically related, and thus if there was a
common-source outbreak, we analyzed the isolates for restriction
fragment length polymorphisms (RFLPs) by using the CARE-2 probe. CARE-2
hybridizes specifically to genomic DNA of C. albicans and
not to that of other Candida species (3). CARE-2
hybridized to 12 to 17 EcoRI restriction endonuclease
fragments per strain, ranging in size from 23 to 1.0 kb (Fig.
1). CARE-2 hybridization profiles were
identical for case patient 3 (Fig. 1, lane 3) and case patient 2 (Fig.
1, lane 4), but these clearly differed from the CARE-2 hybridization
profiles observed for patients 1 and 4 (Fig. 1, lanes 5 and 6, respectively), the four nonoutbreak reference isolates (Fig. 1, lanes 7 to 10), a C. albicans isolate from a randomly chosen
hospital A patient (i.e., unassociated with the outbreak) (Fig. 1, lane
1), and a C. albicans isolate from anesthesiologist 1 (Fig.
1, lane 2). The patterns of CARE-2 hybridization bands for case patient
1 and case patient 4 also were identical but were clearly different
from the CARE-2 hybridization patterns observed for C. albicans isolates from case patients 2 and 3 and from those of the
other isolates in the panel. To confirm this observation, genomic DNA
was digested with a second restriction endonuclease, HincII.
CARE-2 hybridization profiles observed for HincII-digested
samples for case patients 2 and 3 and for case patients 1 and 4 were
identical, but the case patient profiles were significantly different
from the profiles observed for the other isolates analyzed in the panel
(data not shown).

View larger version (100K):
[in this window]
[in a new window]
|
FIG. 1.
Hybridization of digoxigenin-labeled CARE-2 DNA probe to
EcoRI-digested genomic DNA. Lane 1, control patient,
hospital A, C. albicans isolate; lane 2, anesthesiologist 1, hand C. albicans isolate; lane 3, case patient 3; lane 4, case patient 2; lane 5, case patient 1; lane 6, case patient 4; lane 7, control 1 C. albicans isolate; lane 8, control 2 C. albicans isolate; lane 9, control 3 C. albicans
isolate; lane 10, bacteriophage lambda DNA digested with
HindIII used as a molecular size marker (sizes are shown
on the right of the gel).
|
|
The ethidium bromide-stained chromosomes resolved by TAFE for C. albicans isolates from patients 1 (Fig. 1, lane 4) and 4 (Fig. 1,
lane 5) included an extra band not present in the patterns observed for
C. albicans isolates from patients 2 (Fig. 1, lane 3) and 3 (Fig. 1, lane 2), suggesting that these isolates were different (Fig.
2).

View larger version (108K):
[in this window]
[in a new window]
|
FIG. 2.
Ethidium bromide-stained gel following TAFE. Lane 1, anesthesiologist 1, hand C. albicans isolate; lane 2, case
patient 3; lane 3, case patient 2; lane 4, case patient 1; lane 5, case
patient 4; lane 6, control 1 C. albicans isolate; lane 7, control 2 C. albicans isolate; lane 8, control 3 C. albicans isolate.
|
|
 |
DISCUSSION |
The data from our investigation suggest that this unusual cluster
of postsurgical C. albicans infections in patients
undergoing clean and clean-contaminated surgery was due to extrinsic
contamination of the intravenous anesthetic propofol. The findings of
our analysis that are consistent with this hypothesis are the
associations of C. albicans postsurgical infection with the
receipt of propofol by the infusion pump and with preparation and
administration of the infusion pump by a single anesthesiologist,
anesthesiologist 9.
Cultures of this anesthesiologist's hands, performed at the time of
our investigation 2 months after the case-patients' surgical procedures, were negative for C. albicans, although
coagulase-negative Staphylococcus species, Aspergillus
fumigatus, and Candida parapsilosis were isolated. The
large proportion of anesthesiologists in this hospital colonized with
Candida species, compared with rates from other hospitals,
suggests that there was an increased risk of transient hand
colonization with Candida species at hospital A. Other
studies have shown wide variation (15 to 54%) in Candida sp. colonization on hands of health care workers (10, 11).
The likely mechanism for contamination of propofol was via the hands of
anesthesiologist 9 during manipulation of the anesthetic agent. Reports
from our interviews with anesthesiologists suggest that during the
administration of anesthesia, aseptic technique and infection control
practices were not always followed. In particular, anesthesiologist 9 was reported to prepare multiple syringes of propofol before the first
surgical procedure of the day, to be used throughout the day. In
addition, he reused multiple syringes for propofol administration on
the same patient during the surgical procedure.
Propofol is an intravenous hypnotic anesthetic agent which received
Food and Drug Administration (FDA) approval in 1989. Propofol is a
sterile, nonpyrogenic, white soybean-oil-in-water emulsion to be used
by intravenous delivery for induction (by bolus administration) and/or
maintenance (by drip infusion) anesthesia. The product in use in
hospital A had no preservative, and refrigeration was not recommended
by the manufacturer. Therefore, the association of postsurgical
infections with receipt of propofol by infusion could be explained by
the longer duration of administration, allowing extrinsically
contaminating microorganisms from the hands of the anesthesiologist to
proliferate during the infusion interval. Growth studies performed at
CDC showed that when propofol is inoculated with low numbers
(<101 CFU/ml) of C. albicans, these
microorganisms rapidly proliferate to high numbers at 30°C (86°F):
101 CFU/ml within 5 h and 104 CFU/ml
within 24 h (1). Since 11 June 1996, a preservative (disodium edetate [0.005%] has been added to the propofol parenteral emulsion specifically to retard the rate of growth of microorganisms in
the event of accidental extrinsic contamination.
This study represents one outbreak of postsurgical infections and
endotoxemia associated with extrinsic contamination of propofol investigated by CDC and the first to involve C. albicans
infections. The other propofol-related outbreaks were reported from
multiple states and included postsurgical infections (surgical wound or bloodstream) with different species of microorganisms (2). The investigation of these clusters of postsurgical infections suggests
that patients may experience severe life-threatening complications as a
consequence of breaks in aseptic technique in combination with a drug
that is capable of supporting the rapid growth of microorganisms.
As a result of these investigations, the manufacturer of propofol, in
conjunction with the FDA, revised the label and package inserts and
sent letters to all anesthesiologists, nurse anesthetists, and
registered pharmacists in the United States emphasizing the importance
of using aseptic technique in the preparation and administration of
propofol; an additional warning was added to inform practitioners that
multidosing from single vials may result in contamination and
subsequent infection and that each vial was for a single use only.
Subsequently, a preservative was added to the drug formulation which
acts to retard but not entirely eliminate the growth of microorganisms
and to reduce the risk of nosocomial infections. Although the relative
contributions of such control measures are unknown, there have been no
recent outbreak reports. However, it is entirely possible that
outbreaks are not reported because they indicate a failure of good
infection control practices in the hospital. Propofol is very widely
used in the United States and many other countries, and yet these
infectious outbreaks have predominantly been reported from the United
States. In addition, this is one of only two drugs to hold FDA approval
for use as a sedative in intensive care unit patients, and consequently
many patients may be receiving prolonged intravenous infusions of the drug, which may put them at significant risk for infection.
We applied two highly discriminatory and reproducible molecular
subtyping methods, CARE-2 RFLP and electrophoretic karyotype analysis,
to the case and noncase isolates in an attempt to identify a common
source by determining the clonality of C. albicans that infected four patients. Identical CARE-2 hybridization profiles derived
from two different restriction endonucleases, EcoRI and HincII, were observed for patients 1 and 4 and for patients
2 and 3 (Fig. 1), and these profiles were clearly different from the
profiles observed for the other isolates examined. The results of our
CARE-2 RFLP and electrophoretic karotype analyses were in agreement.
Moreover, CARE-2 hybridization profiles for strains from patients 1 and
4 and patients 2 and 3 differed significantly, suggesting that these
two strains were not minor variants from a common clone or different
due to microevolution (4). One interesting epidemiological
question remains: how was nosocomial transmission possible for two
different strains of C. albicans, on two different days, to
each of two different patients per day? This finding most likely
suggests that multiple strains of C. albicans were carried
on the hands of anesthesiologist 9 during the time of the outbreak and
that these two strains were present in approximately equal numbers
(i.e., transient monoclonal or stable polyclonal colonization).
Colonization of healthy individuals by multiple strains at the same
anatomic site has been reported previously (9, 13, 14).
However, this is the first report of multiple-strain carriage causing
nosocomial infections. The possibility of transmission by multiple
exogenous sources cannot, however, be entirely ruled out, since
C. albicans was not isolated from anesthesiologist 9's hand
cultures. This investigation reinforces the benefits of a combined
epidemiological and molecular analysis.
Our investigation emphasizes that all personnel administering
anesthesia in hospitals should receive in-service training in infection
control and aseptic preparation of intravenous medications and
solutions. The infection control quality assurance program should
include periodic observation and review of anesthesia practice. Strict
aseptic technique must always be maintained during handling of
propofol; however, its earlier capability of supporting the rapid
growth of microorganisms may have been modified by the recent addition
of preservative to the drug's formulation. Propofol should be drawn
into sterile syringes immediately after the ampules are opened, and
administration should then begin without extended delay. Propofol
should be prepared for single-patient use only, and any unused portion
should be discarded at the end of the surgical procedure.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Bacterial and Mycotic Diseases, National Center for Infectious
Diseases, Mailstop C-23, CDC, Atlanta, GA 30333. Phone: (404) 639-4697. Fax: (404) 639-3059. E-mail: mmm2{at}cdc.gov.
 |
REFERENCES |
| 1.
|
Arduino, M. R.,
L. A. Bland,
S. K. McAllister,
S. M. Aguero,
M. E. Villarino,
M. M. McNeil, et al.
1991.
Microbial growth and endotoxin production in the intravenous anesthetic propofol.
Infect. Control. Hosp. Epidemiol.
12:535-539[Medline].
|
| 2.
|
Bennett, S. N.,
M. M. McNeil,
L. A. Bland,
M. J. Arduino,
E. Villarino,
D. M. Perrotta, et al.
1995.
Postoperative infections traced to contamination of an intravenous anesthetic, propofol.
N. Engl. J. Med.
333:147-154[Abstract/Free Full Text].
|
| 3.
|
Lasker, B. A.,
L. S. Page,
T. J. Lott, and G. S. Kobayashi.
1992.
Isolation, characterization, and sequencing of Candida albicans repetitive element 2.
Gene
116:51-57[Medline].
|
| 4.
|
Lockhart, S. R.,
J. J. Fritch,
A. Sturdevant Meier,
K. Schoppel,
T. Srikantha,
R. Galask, and D. R. Soll.
1995.
Colonizing populations of Candida albicans are clonal in origin but undergo microevolution through C1 reorganization as demonstrated by DNA fingerprinting and C1 sequencing.
J. Clin. Microbiol.
33:1501-1509[Abstract].
|
| 5.
|
Lott, T. J.,
R. J. Kuykendall,
S. F. Welbel,
A. Paraminik, and B. A. Lasker.
1993.
Genetic heterogenicity in the yeast Candida parapsilosis.
Curr. Genet.
23:463-467[Medline].
|
| 6.
|
Mahrous, M.,
T. J. Lott,
S. A. Mayer,
A. D. Sawant, and D. G. Ahearn.
1990.
Electrophoretic karyotyping of typical and atypical Candida albicans.
J. Clin. Microbiol.
28:876-881[Abstract/Free Full Text].
|
| 7.
|
Maniatis, T.,
E. F. Fritsch, and J. Sambrook.
1982.
Molecular cloning: a laboratory manual.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 8.
|
Mason, M. M.,
B. A. Lasker, and W. S. Riggsby.
1987.
Molecular probe for identification of medically important Candida species and Torulopsis glabrata.
J. Clin. Microbiol.
25:563-566[Abstract/Free Full Text].
|
| 8a.
|
McNeil, M.,
B. Lasker,
T. Lott, and W. Jarvis.
1991.
Abstr. L15, p. 425.
In
Abstracts of the 91st General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
|
| 9.
|
Odds, F. C.,
C. E. Webster,
P. G. Fisk,
V. C. Riley,
P. Mayuranathan, and P. D. Simmons.
1989.
Candida species and C. albicans biotypes in women attending clinics in genitourinary medicine.
J. Med. Microbiol.
29:51-54[Abstract].
|
| 10.
|
Pfaller, M. A.
1995.
Epidemiology of candidiasis.
J. Hosp. Infect.
30(Suppl.):329-338.
|
| 11.
|
Rangel-Frausto, M. S.,
M. A. Martin,
L. Saiman,
H. Blumberg,
J. E. Patterson,
M. A. Pfaller,
R. P. Wenzel, and the NEMIS Study Group.
1994.
Abstr. J106.
In
Program of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 12.
|
Scherer, S., and D. A. Stevens.
1987.
Application of DNA typing methods to epidemiology and taxonomy of Candida species.
J. Clin. Microbiol.
25:675-679[Abstract/Free Full Text].
|
| 13.
|
Soll, D. R.,
R. Galask,
J. Schmid,
C. Hanna,
K. Mac, and B. Morrow.
1991.
Genetic dissimilarity of commensal strains of Candida spp. carried in different anatomical locations of the same healthy women.
J. Clin. Microbiol.
29:1702-1710[Abstract/Free Full Text].
|
| 14.
|
Soll, D. R.,
M. Staebell,
C. Langtimm,
M. Pfaller,
J. Hicks, and T. V. G. Rao.
1988.
Multiple strains in the course of a single systemic infection.
J. Clin. Microbiol.
26:1448-1459[Abstract/Free Full Text].
|
| 15.
|
Thomas, D., and J. Gart.
1977.
A table of exact confidence limits for differences and ratios of two proportions and their odds ratios.
J. Am. Stat. Assoc.
357:72-76.
|
Journal of Clinical Microbiology, May 1999, p. 1398-1403, Vol. 37, No. 5
0095-1137/99/$04.00+0
This article has been cited by other articles:
-
Abdelmalak, B. B., Bashour, C. A., Yared, J. P.
(2008). Skin infection and necrosis after subcutaneous infiltration of propofol in the intensive care unit. Canadian J. Anesthesia
55: 471-473
[Full Text]
-
Trepanier, C. A., Lessard, M. R.
(2003). Propofol and the risk of transmission of infection/Le propofol et le risque de transmission d'infection. Canadian J. Anesthesia
50: 533-537
[Full Text]
-
Lorenz, I. H., Kolbitsch, C., Lass-Florl, C., Gritznig, I., Vollert, B., Lingnau, W., Moser, P. L, Benzer, A.
(2002). Routine handling of propofol prevents contamination as effectively as does strict adherence to the manufacturer's recommendations: [Le maniement d'usage du propofol previent la contamination aussi effectivement que la stricte adhesion aux recommandations du fabricant]. Canadian J. Anesthesia
49: 347-352
[Abstract]
[Full Text]